Navigation Links
Schering-Plough Board Elects Dr. Craig B. Thompson as a Director
Date:1/3/2008

KENILWORTH, N.J., Jan. 3 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP) today announced that its Board had elected Dr. Craig B. Thompson as a member of its Board of Directors, effective Jan. 2, 2008. Dr. Thompson is Director of the Abramson Cancer Center and Professor of Medicine at the University of Pennsylvania School of Medicine in Philadelphia.

Dr. Thompson is an independent director under both the New York Stock Exchange standards and the more restrictive Schering-Plough Board independence standards.

Dr. Thompson, 54, earned an M.D. from the University of Pennsylvania School of Medicine and an AB from Dartmouth College. He chairs the Medical Advisory Board at the Howard Hughes Medical Institute, serves on the advisory boards of St. Jude Children's Research Hospital and M.D. Anderson Cancer Center, and participates in a number of other professional and civic activities.

"Craig's perspective as a scientist and physician will add significant strength to our work as a Board," said Patricia F. Russo, Chair of the Board's Nominating and Corporate Governance Committee. "We are pleased to continue to increase the collective knowledge of the Board with this new member."

"Craig brings deep experience to our Board in the fields of medicine, medical research and fighting cancer, an important priority for humankind. This additional strength on the Board is critical as we continue to increase Schering-Plough's science-focus during our progression along our Action Agenda to transform Schering-Plough into a high-performance, global competitor for the long term," said Fred Hassan, Schering-Plough chairman and chief executive officer.

Schering-Plough is an innovation-driven, science-centered global health care company. Through its own biopharmaceutical research and collaborations with partners, Schering-Plough creates therapies that help save and improve lives around the world. The company applies its research-and-development platform to human prescription and consumer products as well as to animal health products. In November 2007, Schering-Plough acquired Organon BioSciences, with its Organon human health and Intervet animal health businesses, marking a pivotal step in the company's ongoing transformation. Schering-Plough's vision is to "Earn Trust, Every Day" with the doctors, patients, customers and other stakeholders served by its approximately 50,000 people around the world. The company is based in Kenilworth, N.J., and its Web site is http://www.schering-plough.com.


'/>"/>
SOURCE Schering-Plough Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Centocor, Schering-Plough Revise Agreement Covering REMICADE, Golimumab
2. Schering-Plough Declares Quarterly Dividends on Common Shares and 2007 Mandatory Convertible Preferred Stock
3. Schering-Plough Receives Clearance From U.S. Federal Trade Commission for Planned Acquisition of Organon Biosciences N.V.
4. Schering-Plough to Webcast CFO Robert J. Bertolinis Presentation at 2007 Credit Suisse Health Care Conference
5. Schering-Plough Reports U.S. District Court for District of Massachusetts Finds No Liability for Subsidiary in AWP Case
6. Schering-Plough CEO Calls for Four-Pronged Approach to Improving Current Health Care Environment
7. Schering-Plough Reports Financial Results for Third Quarter of 2007
8. Schering-Plough Schedules Conference Call and Webcast for 2007 Third Quarter Earnings
9. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
10. Louise McCormick Joins Heskas Board of Directors
11. Combined Boards Provide Better Care to More Clients More Efficiently
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... CA (PRWEB) , ... February 27, 2017 , ... ... serving San Francisco and environs, is proud to announce an upgrade to the ... on the upgraded Yelp page on topics as diverse as Platelet Rich Plasma ...
(Date:2/26/2017)... ... February 26, 2017 , ... NuevaCare, a leading home care agency based ... and Palo Alto, is proud to announce an important upgrade to its geographic information ... home care close to home, and by having city-specific pages, NuevaCare is answering that ...
(Date:2/26/2017)... ... February 26, 2017 , ... Functional imaging data supports improved ... study released today at the 1st Pan American Parkinson’s and Movement Disorders Congress. ... effective in improving cognitive function in PD patients. This study, led by Ibarretxe-Bilbao ...
(Date:2/24/2017)... ... 2017 , ... Only two months after the official release of The Private ... (France), XO Private has initiated a second print-run of its lavish luxury travel coffee ... across when open, weighs in at more than six kilos, retails at EUR 1,000 ...
(Date:2/24/2017)... ... ... In the Health Care IT campaign, Robert Herjavec discusses health IT security ... will be attacked, but when.” However, he and many others involved highlight a promising ... in auditing and monitoring have taken security in health care a very long way. ...
Breaking Medicine News(10 mins):
(Date:2/27/2017)... , Feb. 27, 2017  Interpace Diagnostics Group, ... provides clinically useful molecular diagnostic tests and pathology services, ... presented at the upcoming United States ... held March 4-10, 2017 in San Antonio, ... a review of data from the Company,s extensive experience ...
(Date:2/27/2017)... Fla. , Feb. 27, 2017 ... focused on developing cerebral embolic protection devices for ... the FDA,s Circulatory System Devices Panel that convened ... need for cerebral protection following transcatheter aortic valve ... by this FDA panel support the need for ...
(Date:2/27/2017)... 2017  RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the ... focused on tissue protection, repair and regeneration, today ... Ltd., received a positive response from the U.S. ... for RGN-137 to treat epidermolysis bullosa ("EB"). RGN-137 ... Thymosin beta 4 ("Tß4") as the active pharmaceutical ...
Breaking Medicine Technology: